Additional Benefits Versus Practicalities of Beta-Blocker Use in CHF Patients: The 'Some Is Better Than None' Rule

Graham Archard


Br J Cardiol. 2005;12(4):313-317. 

In This Article


Beta blockers, previously contra-indicated in the treatment of chronic heart disease, are now established to be a safe and effective drug therapy. Even at doses lower than the clinical trial targets, beta blockers have been shown to have survival benefits. Despite compelling evidence for their mortality benefits and cost-effectiveness, and NICE guidelines promoting their routine use, beta blockers are underprescribed in general practice. Thus, a significant number of patients are receiving suboptimal treatment. Concerns regarding adverse effects of treatment may contribute to the underuse of beta blockers but the practical recommendations of the NICE guidelines should help physicians to initiate and maintain a successful treatment programme.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: